Abstracts tagged "cardiovascular disease and systemic lupus erythematosus (SLE)"

Abstract Number: 707 • 2018 ACR/ARHP Annual Meeting
Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
Monica Vazquez-Del Mercado^1,2, Felipe Perez-Vazquez³, Eduardo Gomez-Bañuelos¹, Efrain Chavarria-Avila³, Arcelia Llamas-Garcia⁴, Karla I. Arrona-Rios⁴, Gustavo I Diaz-Rubio³, Sergio Duran-Barragan⁴, Rosa E Navarro-Hernandez³, Bethel Jordan-Estrada³, Natalia Prado-Bachega⁵, Miguel A. A. Gonzalez-Beltran³, Carlos G Ramos-Becerra⁶, Fernando Grover-Paez⁶, David Cardona-Muller⁷ and Ernesto German Cardona-Muñoz⁷, ¹Servicio de Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ²Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Mexico, ³Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁴Servicio en Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁵Anesthesiology, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁶Centro Universitario de Ciencias de la Salud, INTEC, Universidad de Guadalajara, Guadalajara, Mexico, ⁷Departamento de Fisiología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico
Background/Purpose: It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic…
Abstract Number: 713 • 2018 ACR/ARHP Annual Meeting
Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage
Udi Chorin¹, Aviram Hochstadt¹, David Levartovsky², Irena Litinsky³, Ofir Elalouf⁴, Ari Polachek⁵, Ilana Kaufman⁶, Uri Arad⁷, Valerie Aloush⁷, Sara Borok Lev-Ran⁸, Irena Wigler⁷, Jonathan Wollman⁷, Dan Caspi², Yael Lahat², Or Carmi², Shlomo Berliner⁹, Ori Elkayam⁷, Yan Topilsky¹ and Daphna Paran², ¹Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv Univrsity, Tel Aviv, Israel, ⁶Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁷Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁸Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel AViv, Israel, ⁹Internal Medicine E, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background/Purpose: Subclinical myocardial dysfunction has been reported to occur earlyin SLE. The pathogenesis and prognosis of this finding is not clear. The study aims to…
Abstract Number: 741 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Re-Classification Using Carotid Ultrasound in Systemic Lupus Erythematosus Patients Is Related to the Damage Produced By the Disease
Juan Carlos Quevedo¹, Iñigo Rúa-Figueroa², Hiurma Sanchez-Perez³, Beatriz-Segura Tejera⁴, De Vera-González AM⁵, Alejandra Gonzalez-Delgado⁶ and Iván Ferraz-Amaro⁷, ¹Rheumatology, Hospital Doctor Negrin, Las Palmas GC, Spain, ²Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ³Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ⁴Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, ⁵Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁶Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, ⁷Division of Rheumatology.Hospital Universitario de Canarias, Tenerife, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased in the prevalence of atherosclerosis. Composite scores of cardiovascular risk factors in patients with SLE…
Abstract Number: 1703 • 2018 ACR/ARHP Annual Meeting
Fragmented Qrs in Patients with Systemic Lupus Erythematosus: Relation to the Disease Activity: A Cross-Sectional Study
Masahiro Hosonuma, Nobuyuki Yajima, Ryo Yanai and Ryo Takahashi, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Cardiovascular disease is an important contributor to mortality in Systemic Lupus Erythematosus (SLE). It has been reported that disease activity at diagnosis was associated…
Abstract Number: 709 • 2017 ACR/ARHP Annual Meeting
Characteristics of Cardiac Diseases in Systemic Lupus Erythematosus and Risk Factors of Different Echocardiographic Features
Nevin Hammam^1,2, Mona H EL zohri³ and Alaa A A Mohamed¹, ¹Rheumatology, Rehabilitation and Physical medicine, Assiut University, Faculty of Medicine, Assiut, Egypt, ²Department of Physical therapy, University of Alberta, Edmonton, AB, Canada, ³Internal medicine department, Assiut University, Faculty of Medicine, Assiut, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by involvement of different organs in the body. The cardiovascular (CVD) involvement in SLE is…
Abstract Number: 1841 • 2016 ACR/ARHP Annual Meeting
Dysregulation of the Splicing Machinery Components in Leukocytes from Patients with Systemic Lupus Erythematosus: Influence on Autoimmune and Atherothrombotic Mechanisms
Chary Lopez-Pedrera¹, Sergio Pedraza-Arévalo², Mercedes del Río-Moreno², Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon³, Nuria Barbarroja¹, Yolanda Jiménez-Gómez¹, Ivan Arias de la Rosa³, Eduardo Collantes-Estévez¹, Pedro Segui¹, Maria Jose Cuadrado⁴, Justo P Castaño², Raul M Luque² and Carlos Perez-Sanchez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Department of Cell Biology, Physiology and Immunology. University of Cordoba, Hospital Universitario Reina Sofia (HURS), Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), CIBERobn, and ceiA3, Córdoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing-machinery could influence the development and activity of the disease and the…
Abstract Number: 2833 • 2016 ACR/ARHP Annual Meeting
Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE
Helena Tydén¹, Christian Lood², Andreas Jönsen³, Birgitta Gullstrand⁴, Bjorn Dahlback⁵ and Anders A. Bengtsson³, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ⁴Department of Clinical Sciences, Division of Rheumatology, Lund University, Lund, Sweden, ⁵Department of Translational Medicine, Division of Clinical Chemistry, Lund University, Skane University Hospital Malmö, Malmö, Sweden
Background/Purpose: Human apoM is a 25kDa apolipoprotein present in 5% of HDL particles in plasma. In mouse models, apoM is antiatherogenic and vasculoprotective and…
Abstract Number: 1178 • 2016 ACR/ARHP Annual Meeting
Is Subclinical Atherosclerosis Prevalent in a French Patient Cohort with Systemic Lupus Erythematosus?
Tess Van Meerhaeghe¹, Alexis Mathian¹, Matthieu Wargny¹, Miguel HIe¹, Micheline Pha¹, Julien Haroche², Fleur Cohen¹, Thi-Huang Du Boutin¹ and Zahir Amoura¹, ¹Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) seems associated with an increased risk of cardiovascular disease. These data are mainly based on studies mostly from North America.…
Abstract Number: 1800 • 2016 ACR/ARHP Annual Meeting
Prevalence of ECG Cardiovascular Abnormalities in Lupus Patients: A Novel Approach Using 5 ECG Elements
Hanan Al Rayes¹, Paula Harvey², Dafna D Gladman³, Arthy Sabapathy¹, Murray Urowitz¹ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus patients are at increased risk for cardiovascular disease (CVD). Chou et al. (Ann Inter Med 2011) found that resting ECG abnormalities, in particular…
Abstract Number: 59 • 2015 ACR/ARHP Annual Meeting
Variation in Heart Failure Hospitalizations Among U.S. Medicaid Recipients with SLE 2000-2010, By Race and Ethnicity
Medha Barbhaiya¹, Candace H. Feldman¹, Hongshu Guan¹, Jose A. Gomez Puerta², Michael A. Fischer³ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Heart failure (HF) is a leading cause of hospital admissions. In the US, Blacks have higher HF prevalence than other racial/ethnic groups. Cardiovascular disease…
Abstract Number: 1803 • 2015 ACR/ARHP Annual Meeting
Serum Adipocyte Fatty Acid-Binding Protein Level Is Elevated in Patients with Systemic Lupus Erythematosus (SLE) but Not Associated with Biophysical Markers of Cardiovascular Disease
Anselm Mak^1,2, Herbert Schwarz³, Nien Yee Kow², Sen Hee Tay⁴ and Lieng Hsi Ling^2,5, ¹National University Health System, Singapore, Singapore, ²Medicine, National University of Singapore, Singapore, Singapore, ³Physiology, National Unversity of Singapore, Singapore, Singapore, ⁴National University of Singapore, Singapore, Singapore, ⁵National Unversity Heart Centre Singapore, National Unversity Health System, Singapore, Singapore
Background/Purpose: Adipocyte fatty acid-binding protein (aFABP) is an intracellular lipid-binding protein expressed in adipocytes and macrophages, particularly in inflammatory conditions. Recently, high circulating serum aFABP…
Abstract Number: 1823 • 2015 ACR/ARHP Annual Meeting
Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation
Luciana Seguro¹, Valéria Caparbo², Eloisa Bonfá¹ and Rosa M R Pereira³, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: SLE is associated with high prevalence of metabolic syndrome and obesity, which can be related to the high risk of cardiovascular events in this…
Abstract Number: 1854 • 2015 ACR/ARHP Annual Meeting
Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Eduardo Collantes-Estevez¹, Mª Jose Cuadrado², Rocio Gonzalez-Conejero³, Constantino Martinez³ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: 1) To identify and characterize miRNAs related to the pathogenesis of CVD in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) patients; 2) To…
Abstract Number: 2640 • 2014 ACR/ARHP Annual Meeting
Prevalence and Predictors of ECG Cardiovascular Abnormalities in Lupus Patients
Zahi Touma¹, Paula Harvey², Dafna D. Gladman³, Dominique Ibanez¹, Arthy Sabapathy³ and Murray B. Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with lupus are at increased risk for cardiovascular disease. Previous studies on healthy adults showed that abnormalities detected on resting electrocardiography (ECG)…
Abstract Number: 886 • 2013 ACR/ARHP Annual Meeting
Lupus Neutrophil Extracellular Traps Render High Density Lipoprotein Oxidized and proatherogenic
Carolyne K. Smith¹, Anuradha Vivekanandan-Giri², Jason S. Knight³, Paul Ryan Thompson⁴, Subramaniam Pennathur² and Mariana J. Kaplan⁵, ¹Rheumatology and Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, ²Internal Medicine/Nephrology, University of Michigan Nephrology, Ann Arbor, MI, ³Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴The Scripps Research Institute, Jupiter, FL, ⁵Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Cardiovascular risk is significantly increased in systemic lupus erythematosus (SLE) patients. This phenomenon cannot be explained by the Framingham risk equation. Previous reports suggest that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].